A Multicenter Study of Ibrutinib and Lenalidomide in Combination With DA-EPOCH-R in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 12 Feb 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Pegfilgrastim; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pharmacyclics
- 14 Jan 2019 Status changed from active, no longer recruiting to completed.
- 26 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Nov 2017.
- 18 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.